Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jan 12;17(2):542-543.
doi: 10.5114/aoms/132304. eCollection 2021.

Drucebo effect - the challenge we should all definitely face!

Maciej Banach  1 , Peter E Penson  2
Affiliations
Comment

Drucebo effect - the challenge we should all definitely face!

Maciej Banach et al. Arch Med Sci. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Peter E. Penson owns four shares in AstraZeneca PLC and has received honoraria and/or travel reimbursement for events sponsored by AKCEA, Amgen, AMRYT, Link Medical, Mylan, Napp, Sanofi; Maciej Banach – speakers bureau: Abbott/Mylan, Akcea, Amgen, Daichii Sankyo, KRKA, MSD, Novartis, Novo-Nordisk, Polpharma, Sanofi, Servier; consultant to Akcea, Amgen, Daichii Sankyo, Esperion, Freia Pharmaceuticals, MSD, Polfarmex, Resverlogix, Sanofi/Regeneron; Grants from Amgen, Mylan, Sanofi, and Valeant.

Comment on

  • N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects.
    Wood FA, Howard JP, Finegold JA, Nowbar AN, Thompson DM, Arnold AD, Rajkumar CA, Connolly S, Cegla J, Stride C, Sever P, Norton C, Thom SAM, Shun-Shin MJ, Francis DP. Wood FA, et al. N Engl J Med. 2020 Nov 26;383(22):2182-2184. doi: 10.1056/NEJMc2031173. Epub 2020 Nov 15. N Engl J Med. 2020. PMID: 33196154 Clinical Trial. No abstract available.

References

    1. Wood FA, Howard JP, Finegold JA, et al. N-of-1 trial of a statin, placebo, or no treatment to assess side effects. N Engl J Med. 2020;383:2182–4. - PubMed
    1. Gupta A, Thompson D, Whitehouse A, et al. ASCOT Investigators Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet. 2017;389:2473–81. - PubMed
    1. Rosenson RS, Baker S, Banach M, et al. Optimizing cholesterol treatment in patients with muscle complaints. J Am Coll Cardiol. 2017;70:1290–301. - PubMed
    1. Serban MC, Colantonio LD, Manthripragada AD, et al. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J Am Coll Cardiol. 2017;69:1386–95. - PubMed
    1. Cybulska B, Kłosiewicz-Latoszek L, Penson PE, Nabavi SM, Lavie CJ, Banach M, International Lipid Expert Panel (ILEP) How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors. Prog Cardiovasc Dis. 2020 doi: 10.1016/j.pcad.2020.12.008. - DOI - PubMed

LinkOut - more resources